{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:13:49Z","timestamp":1790108029747,"version":"4.0.1"},"reference-count":54,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Pharmacovigilance systems have flagged possible associations between mRNA COVID-19 vaccination and systemic autoimmune inflammatory rheumatic diseases (AIRDs), generating uncertainty for rheumatologists counselling patients. As the first population-scale deployment of an mRNA vaccine platform, COVID-19 vaccination provides a unique setting to examine whether autoimmune safety signals detected in spontaneous reporting systems correspond to measurable disease risk. We synthesised pharmacovigilance and population-based evidence on incident EULAR-defined systemic AIRDs after mRNA COVID-19 vaccination and assessed whether disproportionality signals were corroborated by analytical studies. Methods: We conducted a PRISMA 2020-compliant systematic review searching MEDLINE, Web of Science, Scopus, Embase, and the Cochrane Library from 2019 to April 2026, supplemented by medRxiv and trial registries. Eligible studies included pharmacovigilance disproportionality analyses and analytical studies, including cohorts and randomised controlled trials, evaluating BNT162b2 or mRNA-1273 in adults without known pre-existing autoimmune disease. Risk of bias was assessed using READUS-PV, ROBINS-I, and RoB 2. Meta-analysis was not performed because of substantial heterogeneity. Results: Fourteen studies were included: seven pharmacovigilance studies and seven analytical studies. Disproportionality analyses suggested increased reporting of selected AIRDs, most consistently polymyalgia rheumatica and giant cell arteritis, mainly when all other adverse-event reports served as comparators. These signals were largely neutral when influenza vaccines were the reference. Across analytical studies, associations were inconsistent; modest increases in systemic lupus erythematosus appeared only in selected analyses. Long-term evidence was scarce: only four studies, from three countries (South Korea, Israel, and Norway), followed participants for up to approximately one year, and three of these reported at least one positive association\u2014systemic lupus erythematosus, post-booster rheumatoid arthritis, and polymyalgia rheumatica in older adults\u2014whereas studies restricted to risk windows of three months or less reported no increase. Conclusions: The available evidence does not indicate a consistent increase in incident systemic AIRDs after mRNA COVID-19 vaccination. Although pharmacovigilance studies identified comparator-dependent signals for selected diseases, particularly polymyalgia rheumatica and giant cell arteritis, these findings were generally not confirmed in comparative population-based studies and should be considered hypothesis-generating. Delayed-onset disease remains poorly characterised, and studies with at least one year of follow-up are needed.<\/jats:p>","DOI":"10.3390\/vaccines14080706","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:01:26Z","timestamp":1786968086000},"page":"706","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparator-Dependent Safety Signals for Incident Systemic Autoimmune Rheumatic Diseases After mRNA COVID-19 Vaccination: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Larisa","family":"Pinte","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Internal Medicine, Department of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Cochrane Romania Affiliate Centre, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Balanescu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-3236","authenticated-orcid":false,"given":"Alina","family":"Dima","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Internal Medicine, Department of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Mandescu","sequence":"additional","affiliation":[{"name":"Neurology Department, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela-Emanuela","family":"Simion-Stanciu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Department of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra-Cristiana","family":"Dumitru","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Internal Medicine, Department of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-0098","authenticated-orcid":false,"given":"Cristian","family":"Baicus","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Internal Medicine, Department of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Cochrane Romania Affiliate Centre, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2468-2667(23)00078-6","article-title":"Reduction in COVID-19-Related Mortality over Time but Disparities across Population Subgroups","volume":"8","author":"Tenforde","year":"2023","journal-title":"Lancet Public Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA Vaccines\u2014A New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2082792","DOI":"10.1080\/21645515.2022.2082792","article-title":"Short-Term Side Effects of COVID-19 Vaccines: A Cross-Sectional Study in Jordan","volume":"18","author":"Nassar","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e003022","DOI":"10.1136\/rmdopen-2023-003022","article-title":"Inflammatory Rheumatic Diseases with Onset after SARS-CoV-2 Infection or COVID-19 Vaccination: A Report of 267 Cases from the COVID-19 and ASD Group","volume":"9","author":"Ursini","year":"2023","journal-title":"RMD Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e014544","DOI":"10.1136\/bmjgh-2023-014544","article-title":"Collaboration within the Global Vaccine Safety Surveillance Ecosystem during the COVID-19 Pandemic: Lessons Learnt and Key Recommendations from the COVAX Vaccine Safety Working Group","volume":"9","author":"Chandler","year":"2024","journal-title":"BMJ Glob. Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103670","DOI":"10.1016\/j.autrev.2024.103670","article-title":"Autoimmunity, a Relevant Exclusion Criterion in the Development of MRNA-Based Compounds: A Systematic Review of Clinical Trials Registries","volume":"23","author":"Pinte","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1136\/annrheumdis-2023-eular.5773","article-title":"AB1363 FIRST PRESENTATION OF AUTOIMMUNE RHEUMATIC DISEASES AFTER COVID-19 VACCINATION: A SYSTEMATIC REVIEW","volume":"82","author":"Soto","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103340","DOI":"10.1016\/j.autrev.2023.103340","article-title":"Insights into New-Onset Autoimmune Diseases after COVID-19 Vaccination","volume":"22","author":"Guo","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nune, A., Durkowski, V., Pillay, S.S., Barman, B., Elwell, H., Bora, K., Bilgrami, S., Mahmood, S., Babajan, N., and Venkatachalam, S. (2023). New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A Systematic Review. Vaccines, 11.","DOI":"10.3390\/vaccines11101571"},{"key":"ref_10","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., and Welch, V. Cochrane Handbook for Systematic Reviews of Interventions, Cochrane. Available online: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 Update of EULAR Recommendations for Vaccination in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A Web and Mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_14","unstructured":"(2025, December 14). EndNote\u2014The Best Citation & Reference Management Tool. Available online: https:\/\/endnote.com\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"ref_17","unstructured":"(2025, December 14). Risk of Bias Tools\u2014ROBINS-I V2 Tool. Available online: https:\/\/www.riskofbias.info\/welcome\/robins-i-v2."},{"key":"ref_18","unstructured":"Cochrane Bias (2025, December 14). RoB 2: A Revised Cochrane Risk-of-Bias Tool for Randomized Trials. Available online: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative Signal Detection Using Spontaneous ADR Reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14740","DOI":"10.1038\/s41598-025-98313-4","article-title":"Disproportionality Analysis of European Safety Reports on Autoimmune and Rheumatic Diseases Following COVID-19 Vaccination","volume":"15","author":"Fraenza","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2334084","DOI":"10.1080\/21645515.2024.2334084","article-title":"Polymyalgia Rheumatica and Giant Cell Arteritis Following COVID-19 Vaccination: Results from a Nationwide Survey","volume":"20","author":"Jarrot","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/keab756","article-title":"Risk of Giant Cell Arteritis and Polymyalgia Rheumatica Following COVID-19 Vaccination: A Global Pharmacovigilance Study","volume":"61","author":"Mettler","year":"2022","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E363","DOI":"10.1093\/rheumatology\/keac323","article-title":"Risk of Systemic Vasculitis Following MRNA COVID-19 Vaccination: A Pharmacovigilance Study","volume":"61","author":"Mettler","year":"2022","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Nakao, H., Koseki, T., Kato, K., Yamada, S., Tsuboi, N., Takahashi, K., and Mizuno, T. (2023). COVID-19 MRNA Vaccination Is Associated with IgA Nephropathy: An Analysis of the Japanese Adverse Drug Event Report Database. J. Pharm. Pharm. Sci., 26.","DOI":"10.3389\/jpps.2023.11453"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e15294","DOI":"10.1111\/1756-185X.15294","article-title":"Global Burden of Vaccine-Associated Rheumatic Diseases and Their Related Vaccines, 1967\u20132023: A Comprehensive Analysis of the International Pharmacovigilance Database","volume":"27","author":"Oh","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"152933","DOI":"10.1016\/j.semarthrit.2026.152933","article-title":"Vaccine-Associated Lupus and Related Organ Involvements: A Pharmacovigilance Analysis of VAERS Database 1990\u20132025","volume":"77","author":"Xie","year":"2026","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2023.05.017","article-title":"Risk of Autoimmune Skin and Connective Tissue Disorders after MRNA-Based COVID-19 Vaccination","volume":"89","author":"Ju","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1038\/s41467-024-50656-8","article-title":"Long-Term Risk of Autoimmune Diseases after MRNA-Based SARS-CoV2 Vaccination in a Korean, Nationwide, Population-Based Cohort Study","volume":"15","author":"Jung","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2024.01.025","article-title":"Autoimmune Adverse Event Following COVID-19 Vaccination in Seoul, South Korea","volume":"153","author":"Kim","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.jaut.2022.102830","article-title":"Autoimmune Conditions Following MRNA (BNT162b2) and Inactivated (CoronaVac) COVID-19 Vaccination: A Descriptive Cohort Study among 1.1 Million Vaccinated People in Hong Kong","volume":"130","author":"Li","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1016\/j.vaccine.2024.04.097","article-title":"The Association between BNT162b2 Vaccinations and Incidence of Immune-Mediated Comorbidities","volume":"42","author":"Shani","year":"2024","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/joim.70052","article-title":"New-Onset Autoimmune Disease Following SARS-CoV-2 Infection and MRNA Vaccination in Norway: A Retrospective Cohort Study","volume":"299","author":"Ruiz","year":"2026","journal-title":"J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the MRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e001888","DOI":"10.1136\/rmdopen-2021-001888","article-title":"Changes in Ankylosing Spondylitis Incidence, Prevalence and Time to Diagnosis over Two Decades","volume":"7","author":"Crossfield","year":"2021","journal-title":"RMD Open"},{"key":"ref_36","first-page":"591","article-title":"Global Epidemiology of Rheumatoid Arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global Epidemiology of Systemic Lupus Erythematosus: A Comprehensive Systematic Analysis and Modelling Study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s10067-023-06670-0","article-title":"Incident Autoimmune Diseases in Association with SARS-CoV-2 Infection: A Matched Cohort Study","volume":"42","author":"Tesch","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e17899","DOI":"10.1016\/j.heliyon.2023.e17899","article-title":"Incidence of Giant Cell Arteritis Is Associated with COVID-19 Prevalence: A Population-Level Retrospective Study","volume":"9","author":"Mulhearn","year":"2023","journal-title":"Heliyon"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","article-title":"Autoimmune Post-COVID Vaccine Syndromes: Does the Spectrum of Autoimmune\/Inflammatory Syndrome Expand?","volume":"41","author":"Jara","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1038\/s41467-024-51411-9","article-title":"Innate Immune Responses against MRNA Vaccine Promote Cellular Immunity through IFN-\u03b2 at the Injection Site","volume":"15","author":"Kim","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11910-024-01386-3","article-title":"The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis","volume":"25","author":"Labowsky","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ard-2024-225492","article-title":"What Rheumatologists Need to Know about MRNA Vaccines: Current Status and Future of MRNA Vaccines in Autoimmune Inflammatory Rheumatic Diseases","volume":"83","author":"Park","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00002018-200427120-00003","article-title":"Data Quality Management in Pharmacovigilance","volume":"27","author":"Lindquist","year":"2012","journal-title":"Drug Saf."},{"key":"ref_45","unstructured":"Gliklich, R.E., Dreyer, N.A., and Leavy, M.B. (2014). Adverse Event Detection, Processing, and Reporting."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e40204","DOI":"10.1097\/MD.0000000000040204","article-title":"Polymyalgia Rheumatica Following COVID-19 Vaccination: Case Series of 3 Patients and Literature Review on Polymyalgia Rheumatica Induced by Various Vaccines","volume":"103","author":"Irani","year":"2024","journal-title":"Medicine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Montano, D. (2022). Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. Front. Public Health, 9.","DOI":"10.3389\/fpubh.2021.756633"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"ofae067","DOI":"10.1093\/ofid\/ofae067","article-title":"Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of MRNA-1273","volume":"11","author":"Urdaneta","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e005138","DOI":"10.1136\/rmdopen-2024-005138","article-title":"Risk of New-Onset Polymyalgia Rheumatica Following COVID-19 Vaccination in South Korea: A Self-Controlled Case-Series Study","volume":"11","author":"Woo","year":"2025","journal-title":"RMD Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40264-026-01650-0","article-title":"Giant Cell Arteritis Following COVID-19 Vaccination: A Consumer-Stimulated Analysis","volume":"49","author":"Shetty","year":"2026","journal-title":"Drug Saf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14760584.2025.2487542","article-title":"Safety Profile of Self-Amplifying MRNA SARS-CoV-2 Vaccine ARCT-154 in Adults: A Pooled Phase 1\/2\/3 Randomized Clinical Study","volume":"24","author":"Ho","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hashiguchi, M., Imai, S., Uehara, K., Maruyama, J., Shimizu, M., and Mochizuki, M. (2015). Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144263"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The Reporting Odds Ratio and Its Advantages over the Proportional Reporting Ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e70043","DOI":"10.1111\/1756-185X.70043","article-title":"Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients with Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study","volume":"28","author":"Shaharir","year":"2025","journal-title":"Int. J. Rheum. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/706\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:18:11Z","timestamp":1786969091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vaccines14080706"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14080706","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}